United States

Mesoblast Ltd (MSB.AX)

MSB.AX on Australia Stock Exchange

28 Apr 2017
Change (% chg)

$-0.17 (-5.12%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Mesoblast says co received $6.2 mln from Australian government for R&D
Thursday, 19 May 2016 07:55pm EDT 

Mesoblast Ltd : Mesoblast receives $6.2 million from Australian government for research and development activities . Anticipates that it will continue to receive Australian government funds for ongoing research and development activities undertaken during FY 2016 .  Full Article

Mesoblast Ltd announces pricing of public offering on Nasdaq
Friday, 13 Nov 2015 08:39am EST 

Mesoblast Ltd:Says initial public offering of 7.5 million ads priced at $8.00/ADS.  Full Article

Celgene and Mesoblast extend agreement
Thursday, 15 Oct 2015 07:50pm EDT 

Mesoblast:Says it has agreed with Celgene Corporation to extend for a period of six months Celgene's right of first refusal.Agreement with respect to Mesoblast's proprietary mesenchymal lineage adult stem cell product candidates for the prevention and treatment of acute graft versus host disease (GVHD), certain oncologic diseases, inflammatory bowel diseases, and organ transplant rejection.  Full Article

Mesoblast Limited announces positive trial results of mesoblast cell therapy in patients with diabetes and advanced chronic kidney disease
Monday, 8 Jun 2015 06:38pm EDT 

Mesoblast Limited:Announces that results from the company's Phase 2 trial in patients with diabetic nephropathy showed that a single infusion of its intravenously delivered allogeneic mesenchymal precursor cell (MPC) product candidate MPC-300-IV was safe.Says it reduced damaging inflammation, and preserved or improved renal function over at least 24 weeks.  Full Article

More From Around the Web

BRIEF-Mesoblast receives A$3.7m from Australian Government for research and development

* Asx alert-Mesoblast receives A$3.7m from AUS Government for research and development-MSB.AX Source text for Eikon: Further company coverage: